Quest Diagnostics Launches New Molecular Test Panel for Enhanced Thyroid Cancer Detection
Published on Friday, 01 June 2012 13:41 Written by TradersHuddle Staff
Results of a study of the test panel to be unveiled at the 2012 ASCO Annual Meeting on June 4; new test may reduce risk of surgical removal of healthy thyroids for some patients
MADISON, N.J., June 1, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced a new molecular test panel designed to help physicians determine if a thyroid gland is cancerous and requires surgical removal. The test is believed to be the most comprehensive panel clinically available to identify mutations associated with four gene markers indicated by the American Thyroid Association for the clinical management of indeterminate thyroid biopsies.
"The removal of a healthy thyroid gland is an unfortunate outcome for many patients, due to limitations of current test methods," said Richard E. Reitz, M.D., medical director and chair, Endocrine Division, Quest Diagnostics Nichols Institute, the advanced diagnostic testing, research and development center of Quest Diagnostics. "We believe our molecular panel will enhance the reliability of thyroid biopsy testing, helping to prevent the unnecessary removal of healthy thyroids for many patients."
The Quest Diagnostics Thyroid Cancer Mutation Panel aids in detecting cancer in thyroid biopsies which are found to be indeterminate for cancer by current cytology test methods. Approximately 15% to 20% of these biopsies, which are collected by fine needle aspiration (FNA), produce indeterminate results. An unclear result may increase the risk that a physician, in an abundance of caution, will biopsy additional tissue using a larger needle or surgically remove part or all of a thyroid suspected of having cancer that is later diagnosed as healthy. About 300,000 thyroid FNA biopsy procedures are performed annually in the United States.
The new panel identifies mutations of the molecular markers BRAF V600E, RAS, RET/PTC, and PAX8/PPAR gamma, which are associated with papillary and follicular thyroid cancer, two common forms of the disease. Practice guidelines from the American Thyroid Association recommend that physicians consider these markers as aids in clinical management of patients with indeterminate biopsy test results. The test complements the company's FNA cytology testing services for thyroid biopsies, and may be used on FNA biopsies ruled indeterminate by these testing services.
Results of a study by scientists at Quest Diagnostics found that 90 of 149 FNA specimens, or about 60%, had mutations of one or more of the four markers tested by the new panel. The presence of the four markers was generally mutually exclusive, suggesting potential value in a hierarchical screening strategy for samples with limited tissue. According to the American Cancer Society, about two tests in every 10 may need to be repeated because the sample does not contain enough cells for testing.
Dr. Reitz will describe the findings during an oral presentation at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 4 from 12:30 to 12:45 PM at McCormick Place in Chicago (Location: E354a). The abstract is available online at: http://abstract.asco.org/AbstView_114_94089.html
The thyroid is a gland located in the neck that influences the body's metabolic processes. Without a thyroid, a patient must take supplemental hormone therapy indefinitely to prevent hypothyroidism. As many as 54,500 new cases of thyroid cancer will be diagnosed in the United States in 2012.
In addition, the company has introduced the Quest Diagnostics Thyroglobulin (Tg) Post-treatment Monitoring Test to aid in monitoring for recurrence of cancer following surgery. Thyroid cancers can cause blood levels of Tg to rise, providing a marker for recurrence. However, these cancers can also cause auto-antibodies (anti-TG) to rise, hindering reliable Tg measurement in 20% to 30% of cases. The new Quest Diagnostics test is believed to be the first for clinical use to use liquid chromatography tandem mass spectrometry (LC/MS/MS), a highly sensitive analytical technique, to confirm and measure Tg in anti-TG positive specimens tested by immunoassays.
Quest Diagnostics will provide information about its thyroid and other cancer testing services at booth 6129 during the 2012 ASCO Annual Meeting, June 1-5.
About Quest Diagnostics
Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at QuestDiagnostics.com. Follow us at Facebook.com/QuestDiagnostics and Twitter.com/QuestDX.
Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks are the property of their respective owners.
Quest Diagnostics Contacts:
Wendy Bost (Media): 973-520-2800
Kathleen Valentine (Investors): 973-520-2900
SOURCE Quest Diagnostics
- Quest Diagnostics Declares Quarterly Cash Dividend
- Quest Diagnostics Acquires Concentra's Laboratory Business, Enters into Exclusive Services Agreement
- Decades of Improving Cholesterol Levels Abruptly Ended in 2008, PLOS ONE Study Finds
- Quest Diagnostics to Speak at the Bank of America Merrill Lynch 2013 Health Care Conference
- Quest Diagnostics Reports First Quarter 2013 Financial Results
- Quest Diagnostics to Acquire Lab-Related Clinical Outreach Operations of Dignity Health in California and Nevada
- Quest Diagnostics Names Jim Davis, Senior Vice President, Diagnostic Solutions
- Quest Diagnostics Completes Sale of HemoCue Business to Radiometer Medical ApS
- Quest Diagnostics Launches Novel Rheumatoid Arthritis Tests
- Recreational Marijuana Users More Likely To Misuse Prescription Drugs, According to National Study by Quest Diagnostics
Related Partner Headlines
- UPDATE: Canaccord Genuity Reduces PT to $59 on Quest Diagnostics - Benzinga
- Quest Sees Deal Neutral to EPS in FY12; Adding to EPS in FY13 - Benzinga
- Quest Diagnostics Says Will Cut 400-600 Management Jobs; Create 2 New Business Structures - Benzinga
- Quest Reaches New 52-Week High (DGX) - TheStreet.com
- Quest Stock To Go Ex-dividend Tomorrow (DGX) - TheStreet.com
- UPDATE: Credit Suisse Assumes Coverage on Quest Diagnostics with Neutral Rating, $67 PT - Benzinga
- Quest Diagnostics Inc (DGX): Today's Featured Health Services Winner - TheStreet.com
- Quest Stock Hits New 52-Week High (DGX) - TheStreet.com
- UPDATE: Goldman Sachs Upgrades Quest Diagnostics to Neutral on Defensiveness, New CEO - Benzinga
- Quest Stock To Go Ex-dividend Tomorrow (DGX) - TheStreet.com
Latest Partner Headlines
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com
Separating the Bargains From the Busts - TheStreet.com
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com
Gap Up and Sit - TheStreet.com
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com
Windows 8 PC Sales Disappointing: Report - TheStreet.com
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Dow JonesCompany ID [INDEXDJX:.DJI] Last trade:15,307.17 Trade time:4:44PM EDT Value change:▼80.41 (-0.52%)
S&P 500Company ID [INDEXSP:.INX] Last trade:1,655.35 Trade time:4:43PM EDT Value change:▼13.81 (-0.83%)
NASDAQCompany ID [INDEXNASDAQ:.IXIC] Last trade:3,463.30 Trade time:5:15PM EDT Value change:▼38.82 (-1.11%)
In The Wires
Bristow Group Reports Financial Results For Its 2013 Fiscal Fourth Quarter And Year Ended March 31, 2013
Amgen Announces Voting Results of Annual Meeting of Stockholders
CenturyLink to receive additional Connect America Funds
Domino's Pizza to Join S&P MidCap 400; Cynosure to Join S&P SmallCap 600
Ross Stores Announces Quarterly Dividend
EastGroup Properties Announces Recent Investments
Cash Dividend And Stock Repurchase Program Announced At Valley Commerce Bancorp's 2013 Annual Shareholders' Meeting
Questar Assessment Experts to Present at Upcoming CCSSO 43rd Annual National Conference on Student Assessment